Age, biological sex, genetic constitution, and current or chronic disease status are among the pivotal factors influencing how drugs interact with each other and our bodies. A “one-size-fits-all” strategy in drug therapy is therefore often inadequate, especially when dealing with the simultaneous prescription of multiple medications, which increases the risk of serious side effects. Changing the state of the art and working towards the implementation of personalised drug therapy is essential to reduce hospitalisations and deaths attributed to adverse drug reactions.

The EU-funded SafePolyMed project is on such an ambitious mission, with 12 international partners working to provide physicians, pharmacists, and patients with innovative tools to define, assess, and manage drug interactions on an individual level. The project is also designing a new approach to involve and empower patients in managing their healthcare proactively.

CMLAN is proud to be part of a dedicated network of patient organizations, the Patient Engagement Hub, within the European project SafePolyMed, focused on improving patient-centered healthcare in the area of polypharmacy. Together, we are working to address the complex issue of polypharmacy, which significantly affects the well-being of many, including those in our own community. By contributing to advancements in managing complex medications, highlighting the consequences and identification of drug-drug interactions and drug-drug-gene interactions, we are committed to ensuring that patients receive safer, more personalized care.